W Brennen N, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJin, Chapman C, Abdallah R, Levy O, Bhowmick NA, et al. In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cell-Based Drug Delivery. Stem Cells Transl Med. 2019.